

Special Issue

Acute Myeloid Leukemia: Current Progress and Future Directions

Message from the Guest Editors

Acute myeloid leukemia (AML) is an aggressive malignancy spanning heterogeneous clinical and molecular phenotypes. In recent years, huge advances in our understanding of the disease's biology have led us to gain deeper insight into the genetic features and the bone marrow microenvironment changes underpinning the process of leukemogenesis, paving the way to targeted treatments. This Special Issue will focus on the recent advances concerning all facets of personalized AML management, including both treatment investigations and translational research, as well as the bench-side management of complications and all-day practice. Moreover, current and future risk disease stratifications, prognostic markers and models, and applications of novel techniques regarding the disease's multimodal nature will be considered. We will highly appreciate and welcome the submissions of original papers and reviews in line with the aim of this Special Issue.

Guest Editors

Dr. Valeria Visconte

Department of Translational Hematology and Oncology Research,
Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA

Dr. Luca Guarnera

1. Department of Translational Hematology & Oncology Research,
Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

2. Department of Biomedicine and Prevention, Tor Vergata University,
Rome, Italy

Deadline for manuscript submissions

10 December 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed




mdpi.com/si/211642

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).